JPRN-jRCT1080220199未知2 期
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer
Taiho Pharmaceutical Co., Ltd. DAIICHI SANKYO Co., Ltd.0 个研究点开始时间: 2006年1月25日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Histologically confirmed colorectal cancer
- •Locally advanced and/or metastatic colorectal cancer
- •Have prior chemotherapy as first line treatment
- •Age 20 to 75
- •Performance status 0 or 1 (ECOG)
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Phase II study of a combination of CPT-11, 5FU/l-LV and UFT/LV in patients with advanced/recurrent colorectal canceradvanced/recurrent colorectal cancerJPRN-UMIN000000613Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)40
已完成
2 期
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal CancerColorectal CancerNCT00284258Taiho Pharmaceutical Co., Ltd.426
已完成
2 期
PhaseII study of 5-FU/I-LV+L-OHP+CPT-11 combination chemotherapy(FOLFIRINOX) in 1st line treatment for locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000013385Osaka Medical College Hospital45
进行中（未招募）
不适用
Essai de phase II : Folfiri.3 (CPT-11/acide folinique/5-FU) / gemzar en traitement sequentiel des cancers du pancréas métastatiques non pré-traités - firgemEUCTR2006-005703-34-FRAgeo
未知
2 期
A phase 2 trial of FOLFIRINOX in patients with previously untreated metastatic pancreatic cancerpreviously untreated pancreatic cancerJPRN-jRCT2080221426Yakult Honsha Co.,Ltd.35